Special Issue "Modes of Antibody Action for Cancer Therapy"

Guest Editor
Prof. Dr. Patrick A. Baeuerle
Micromet, Inc., 9201 Corporate Blvd., Suite 400, Rockville, MD 20850, USA
Website: http://www.micromet.com/About/OurTeam/Management.aspx
E-Mail: patrick.baeuerle@micromet.com
Interests: bispecific antibodies; T cells; antibody drug conjugates; Fc-engineered antibodies; cancer therapy; antibody targets

Dear Colleagues,

Antibody-based therapies have high potential to treat malignant diseases. Very different modes of action can be employed to this end. There are intrinsic properties of antibodies such as ADCC, which can be enhanced by Fc gamma engineering, CDC, or an anti-apoptotic activity induced by antibody binding to a specific target antigen. There are also ways of bolting onto antibodies toxic compounds for improving efficacy. Conjugation of antibodies with plant or bacterial toxins leads to immunotoxins, with chemotherapeutics to antibody drug conjugates (ADCs), and with radioisotopes to radioimmunoconjugates. Bispecific antibodies have the potential to inhibit at a time two receptors, neutralize two angiogenic factors, or combinations thereof. Bispecific antibodies can also be used to tether T cells to cancer target cells, which is not possible with conventional antibodies. Lastly, antibodies binding to immune regulatory receptors can significantly  support natural or antibody-mediated immune reactions against tumors. For each class, there are now drug candidates under late-stage development, or on the market. A special issues with focus on "modes of antibody action against cancer" will review recent developments and allow comparison of these different modes of action.

Prof. Dr. Patrick A. Baeuerle
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

• antibody-dependent cellular cytotoxicity (ADCC)
• complement-dependent cytotoxicity (CDC)
• antibody drug conjugates
• immunotoxins
• immunocytokines
• radioimmuno conjugates
• Fc gamma engineering
• bispecific antibodies
• T or NK cell engaging antibodies
• immune-stimulating antibodies